Clinical stage drug development company Telik, Inc. (TELK) posted second-quarter net loss of $2.1 million or $1.11 per share, narrower than $3.0 million or $1.67 per share in the previous year quarter.
Loss from operations narrowed to $2.06 million from $3.01 million in the comparable quarter last year.
For comments and feedback: editorial@rttnews.com